Experienced in Empyema

Yong Q. Fang

58 Zhongshan Second Road, 
Guangzhou, CN 
Experienced in Empyema
58 Zhongshan Second Road, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Yong Fang practices in Guangzhou, China. Fang is rated as an Experienced expert by MediFind in the treatment of Empyema. Their top areas of expertise are Gastrointestinal Stromal Tumor, Scrofula, Squamous Cell Lung Carcinoma, Gastrectomy, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 374 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Empyema.

Locations

58 Zhongshan Second Road, Guangzhou, 510080, China
Other Locations
28 Fuxing Road, Beijing, 100853, China
1095 Jiefang Ave, Wuhan, 430030, China
Xinmin Street 1#, Changchun, 130021, China
Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, 310016, China
180 Fenglin Road, Zhongshan, China
16, Jichang Road, Guangzhou, 510405, China
No. 215 Zhongshan Avenue, Wuhan, 430022, China
180 Fenglin Road, Xuhui, 200032, China
No. 12 Middle Urumqi Road, Shanghai, 200040, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Enrollment Status: Active_not_recruiting
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid Tumors
Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: June 24, 2024
Intervention Type: Drug
Study Drug: Encorafenib
Study Phase: Phase 1
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Enrollment Status: Unknown
Publish Date: March 08, 2023
Intervention Type: Drug
Study Drugs: Pyrotinib, Docetaxel
Study Phase: Phase 3
Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial
Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial
Enrollment Status: Enrolling_by_invitation
Publish Date: August 01, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine inTreating Patients With Advanced Malignant Tumor
Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine inTreating Patients With Advanced Malignant Tumor
Enrollment Status: Unknown
Publish Date: November 16, 2021
Intervention Type: Other, Biological
Study Drugs: Granulocyte Colony-Stimulating Factor, Personalized Neoantigen Cancer Vaccine
Study Phase: Phase 1
View 5 Less Clinical Trials

374 Total Publications

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fang's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile